{"id":390300,"date":"2019-12-20T00:00:00","date_gmt":"2019-12-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfhe0001-2019-biopharma-hemophilia-disease-landscape-and-forecast-hemophilia-a-g7-2019\/"},"modified":"2026-03-31T10:45:51","modified_gmt":"2026-03-31T10:45:51","slug":"dlsfhe0001-2019-biopharma-hemophilia-disease-landscape-and-forecast-hemophilia-a-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfhe0001-2019-biopharma-hemophilia-disease-landscape-and-forecast-hemophilia-a-g7-2019\/","title":{"rendered":"Hemophilia | Disease Landscape and Forecast | Hemophilia A | G7 | 2019"},"content":{"rendered":"<p><abbr title=\"Decision Resources Group\">DRG<\/abbr>\u00a0anticipates the next ten years to be a transitional time in the treatment of hemophilia A for patients with and without inhibitors. With the uptake of Roche \/ Chugai\u2019s bispecific antibody Hemlibra and a diverse pipeline, both in terms of technology type and administration route, we forecast significant changes in disease management. The\u00a0<abbr title=\"research and development\">R&#038;D<\/abbr>\u00a0emphasis has shifted to <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854607517596240229779\">nonfactor<\/gwmw> treatment approaches to restore coagulation. Examples include Sanofi\u2019s anti-ATIII\u00a0<abbr title=\"small interfering RNA\"><gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854607529656366772137\">siRNA<\/gwmw><\/abbr>, <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854607529654877225256\">fitusiran<\/gwmw>, Novo Nordisk\u2019s anti-<abbr title=\"tissue factor pathway inhibitor\">TFPI<\/abbr><abbr title=\"monoclonal antibody\">MAb<\/abbr>, <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854607529650188671177\">concizumab<\/gwmw>, and BioMarin\u2019s gene therapy, BMN 270. Despite novel <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854607540359587168704\">nonfactor<\/gwmw> hemophilia agents forecast to launch, we expect the factor concentrate market to remain competitive, and the high demand for factor concentrates to persist.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>How <gwmw class=\"ginger-module-highlighter-mistake-type-3\" id=\"gwmw-15854607553267265890836\">will physicians treating<\/gwmw> hemophilia A differentiate between the various emerging therapies, and which will gain the greatest market and patient share in an increasingly stringent regulatory environment?<\/li>\n<li>What clinical roles will Hemlibra, <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854607562999896350048\">fitusiran<\/gwmw>, <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854607562998335662075\">concizumab<\/gwmw>, and gene <gwmw class=\"ginger-module-highlighter-mistake-type-6\" id=\"gwmw-15854607562990831717538\">therapy play<\/gwmw> in the evolving hemophilia A treatment landscape?<\/li>\n<li>How will the management of patients with inhibitors change when new treatment options become available? How will Hemlibra\u2019s head start on its competitors play out over the forecast period?<\/li>\n<li>How will the factor VIII concentrate market evolve? How will <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854607591682556643161\">nonfactor<\/gwmw> treatment <gwmw class=\"ginger-module-highlighter-mistake-type-3\" id=\"gwmw-15854607591684929047241\">options<\/gwmw> impact the multitude of brands vying for patient share in this space?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em>\u00a0provides <gwmw class=\"ginger-module-highlighter-mistake-type-3\" id=\"gwmw-15854607611149594226081\">comprehensive market intelligence<\/gwmw> with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390300","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hemophilia","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390300\/revisions"}],"predecessor-version":[{"id":576557,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390300\/revisions\/576557"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}